Dr. Norman B. Gaylis, MD

Dr. Gaylis practices at Arthritis & Rheumatic Disease Specialties in Miami, Florida.

Dr. Gaylis' NPI, 1255440384, was assigned on August 30, 2006. Dr. Gaylis graduated from University of the Witwatersrand in 1973. Dr. Gaylis holds Florida license ME31090.

Dr. Gaylis' primary practice is Arthritis & Rheumatic Disease Specialties, at 21097 Ne 27th Ct, Miami, FL 33180 in Miami-Dade County. The practice phone is (305) 652-6676.

Dr. Gaylis' primary practice is Arthritis & Rheumatic Disease Specialties in Miami, Florida. Dr. Gaylis is also affiliated with Memorial Regional Hospital. The medical group on file is Arthritis & Rheumatic Disease Specialties. Dmand AI also links Dr. Gaylis to 1 more hospital, 1 physician office and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gaylis practices, 4 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Gaylis' primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Gaylis is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Gaylis' licenses on file in 2 states: Florida and Georgia.

Dmand AI lists arteritis, arthritis, fibromyalgia and chronic pain, gout, joint pain, lupus, muscle pain, fibromyalgia, and limb pain and osteoporosis among the conditions Dr. Gaylis treats.

CMS data shows 327,379 Medicare services from Dr. Gaylis across 40 procedure codes in 2024, for 947 Medicare patients. Medicare paid $3,144,229 for them. Every service was in an office.

CMS counts 947 Medicare patients who saw Dr. Gaylis in 2024. The largest group is 75 to 84, with 379 patients. 75% of them have arthritis, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 1.42, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Gaylis' median patient age at 70, with 77% women.

In 2024, Dr. Gaylis wrote 2,500 Medicare Part D claims for 647 patients. 77% of them were for generic drugs. CMS names the drug for 2,291 of them, across 32 drugs with 11 or more claims each, at $2,148,297 in total drug cost. In 2023, CMS named 1,630 claims across 27 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Gaylis for performance year 2024, reported as part of a group. Dr. Gaylis accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 22 papers to Dr. Gaylis, published from 2007 to 2024. 2012 was the busiest year, with 3. The most frequent topics are Arthritis, Rheumatoid, Antirheumatic Agents and Antibodies, Monoclonal, Murine-Derived. Dr. Gaylis has published most often in J Rheumatol. Dr. Gaylis' most frequent co-authors are Charles George Peterfy, MD, PhD, Ewa Olech, MD and Andrew Blauvelt, MD.

Dmand AI links Dr. Gaylis to 15 clinical trials, 7 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Arthritis, Rheumatoid, Rheumatic Diseases and Lupus Erythematosus, Systemic. Eli Lilly and Company sponsors the most, 4. Open Payments lists research payments to Dr. Gaylis that name 5 trials.

CMS Open Payments shows 235 general payments to Dr. Gaylis from 29 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 41% of the total. Novartis Pharmaceuticals Corporation paid the most, $12,805. It also lists 22 research payments totaling $282,986 from 2016 to 2025, naming 5 clinical trials.

Dmand AI lists 3 awards for Dr. Gaylis, most recently Top Doctors:South Florida in 2012.

Dr. Gaylis graduated from University of the Witwatersrand in 1973. Dr. Gaylis is a member of ACR.

Dr. Gaylis is in network with 18 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 12. Check the plan with the practice before a visit.